Pernix Therapeutics Announces Positive Phase IV Results of Silenor® vs. Zolpidem Head-to-Head Arousability Study
June 16, 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
Data demonstrated that Pernix Therapeutics’ Silenor® 6 mg was superior to zolpidem 10 mg on all measures evaluated. Study results presented at SLEEP 2016 international meeting MORRISTOWN, N.J.,...
Pernix Therapeutics Announces the Issuance of Three New Orange Book Patents for Zohydro® ER with BeadTek™
May 25, 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., May 25, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that the United States Patent and Trademark...
Pernix Therapeutics Announces CEO Transition
May 11, 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., May 11, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that Doug Drysdale, after discussions with...
Pernix Therapeutics Overcomes Challenge to Treximet® ‘183 Patent
May 09, 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that on May 6, 2016, the Patent Trial and...
Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update
May 05, 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
Pernix Prescriptions DirectTM Achieves Increased Penetration MORRISTOWN, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a...
Pernix Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016
April 28, 2016 08:30 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., April 28, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that it will release financial results for...
Pernix Therapeutics to Present at Needham & Company’s 15th Annual Healthcare Conference
April 05, 2016 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., April 05, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief...
Pernix Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
March 10, 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
Full Year 2015 Revenue Increases 44% Year-Over-Year to $176 MillionFull Year 2015 Adjusted EBITDA of $31.2 MillionMORRISTOWN, N.J., March 10, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings,...
Pernix Therapeutics Files Citizen Petition Following Issuance of U.S. Patent Number 9,265,760 (‘760 Patent) Covering Safety Information Related to Dosing Patients with Zohydro ER® with BeadTek™ CII
March 02, 2016 08:30 ET
|
Pernix Therapeutics Holdings, Inc.
Morristown, NJ, March 02, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced their submission of a Citizen Petition to...
Pernix Therapeutics to Report Fourth Quarter and Full-Year 2015 Financial Results on Thursday, March 10, 2016
February 24, 2016 08:43 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that it will release its fourth quarter and...